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Image reconstruction
Aim: Combined PET/MR systems have nowbecomeavailable for clinical use. Given the lack of integrated standard
transmission (TX) sources in these systems, attenuation and scatter correction (AC)must be performed using the
available MR-images. Since bone tissue cannot easily be accounted for during MR-AC, PET quantiﬁcation can be
biased, in particular, in the vicinity of the skull. Here, we assess PET quantiﬁcation in PET/MR imaging of patients
using phantoms and patient data.
Materials and methods: Nineteen patients referred to our clinic for a PET/CT exam as part of the diagnostic eval-
uation of suspected dementiawere included in our study. The patients were injectedwith 200 MBq [18F]FDG and
imaged with PET/CT and PET/MR in random sequence within 1 h. Both, PET/CT and PET/MR were performed as
single-bed acquisitions without contrast administration. PET/CT and PET/MR data were reconstructed following
CT-based and MR-based AC, respectively. MR-AC was performed based on: (A) standard Dixon-Water–Fat
segmentation (DWFS), (B) DWFS with co-registered and segmented CT bone values superimposed, and (C)
with co-registered full CT-based attenuation image. All PET images were reconstructed using AW-OSEM, with
neither resolution recovery nor time-of-ﬂight option employed. PET/CT (D) or PET/MR (A–C) images were
decay-corrected to the start time of the ﬁrst examination. PET images following AC were evaluated visually
and quantitatively using 10 homeomorphic regions of interest drawn on a transaxial T1w-MR image traversing
the central basal ganglia.We report the relative difference (%) of themean ROI values for (A)–(C) in reference to
PET/CT (D).
In a separate phantom experiment a 2 L plastic bottlewas layeredwith approximately 12 mmof Gypsumplaster
to mimic skull bone. The phantomwas imaged on PET/CT only and standardMR-ACwas performed by replacing
hyperdense CT attenuation values corresponding to bone (plaster) with attenuation values of water. PET image
reconstructionwas performedwith CT-AC (D) and CT-AC using themodiﬁed CT images corresponding toMR-AC
using DWFS (A).
Results: PET activity values in patients following MR-AC (A) showed a substantial radial dependency when com-
pared to PET/CT. In all patients cortical PET activity was lower than the activity in the central region of the brain
(10–15%). When adding bone attenuation values to standard MR-AC (B and C) the radial gradient of PET activity
values was removed.
Further evaluation of PET/MR activity followingMR-AC (A) relative toMR-AC (C) using the full CT for attenuation
correction showed anunderestimation of 25% in the cortical regions and 5–10% in the central regions of the brain.
Observations in patients were replicated by observations from the phantom study.
Conclusion:Our phantom and patient data demonstrate a spatially varying bias of the PET activity in PET/MR im-
ages of the brain when bone tissue is not accounted for during attenuation correction. This has immediate impli-
cations for PET/MR imaging of the brain. Therefore, reﬁnements to existing MR-AC methods or alternative
strategies need to be found prior to adopting PET/MR imaging of the brain in clinical routine and research.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.gy, Nuclear Medicine and PET,
mark. Fax: +45 3545 3898.
c. Open access under CC BY license.Introduction
Dual-modality imaging by means of integrated imaging systems has
become a mainstay in clinical routine and research (Beyer et al., 2011).
These imaging systems combine Single Photon Emission Tomography
(SPECT) or Positron Emission Tomography (PET) with Computed
207F.L. Andersen et al. / NeuroImage 84 (2014) 206–216Tomography (CT). Recently, a new combination of PET with Magnetic
Resonance Imaging (MRI) has been proposed that offers complementary
or even exclusive information compared to PET/CT. All three dual-
modality combinations provide anato-metabolic image information
(Wahl et al., 1993) that can be used for improved diagnostic assessments
and, thus, stratiﬁed patient management.
The major advantage of SPECT/CT and PET/CT is the intrinsic align-
ment of functional and anatomical image information that is acquired
in a shorter time than the time needed to perform both examinations
independently on separate imaging systems. In addition, the CT images
can be used for attenuation correction of the emission data (Kinahan
et al., 1998; LaCroix et al., 1994), thus, obviating the need for lengthy,
standard transmission scanning using radioactive sources.
However, CT images are limitedwith respect to soft tissue character-
ization and tissue contrast. This limits the usefulness of PET/CT, for
example, in neurology applications, thus, rendering a separate MRI
examination a requirement for many indications. Therefore, combined
PET/MR imaging is expected to provide diagnostic information similar
or better than that of PET/CT, while soft tissue contrast is improved
and patient exposure to ionizing radiation is reduced in PET/MR
(Pichler et al., 2010).
Today, two vendors propose somewhat different design concepts
for whole-body PET/MR imaging systems. In 2010, Philips Healthcare
introduced a sequential PET/MR system combining a time-of-ﬂight
(Budinger, 1983) PET together with a 3T MR (Kalemis et al., 2013;
Zaidi et al., 2011). In 2012, Siemens Healthcare received FDA approval
for a fully-integrated PET/MRI system based on MR-compatible PET de-
tectorsmounted inside theMR system (Delso et al., 2011).While no ev-
idence exists today for the clinical superiority of simultaneous PET and
MRI acquisitions, it is clear that the simultaneous acquisitionwill beneﬁt
a number of research intentions and applications. For example, brain
imaging of neurologic disorders, such as dementia, as well as neuro-Bone 
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Fig. 1. Explanation of the origin of the bias in reconstructed PET(/MR) tracer distribution in (A)
bone. In both A and B, the left half shows a CT-image while the right part shows the attenuation
attenuation of the skull as this is replaced by values of soft tissue. The error for a given line-of-
length of the path through the skull. Since this path-length is longer for LORs near the edge than
through reconstruction to the ﬁnal images resulting in suppression of the edges (cortex).oncology applications will draw from the superior soft-tissue contrast
of MR together with advanced MRI techniques measuring, e.g., water
diffusion or tissue perfusion (Catana et al., 2012; Heiss, 2009).
Despite the advantages of combined PET/MR imaging the adoption
of this newmodality in clinical routine, andmore so in clinical research,
is challenged by the need to perform MR-based attenuation correction
(MR-AC) (Hofmann et al., 2009). For the brain this impacts not only
on basic research-driven applications, such as neuroreceptor kinetic
modeling and quantiﬁcation, but also on the clinical use of PET, includ-
ing brain tumor imaging, and dementia.
Attenuation correction is a pre-requisite for in-vivo PET quantiﬁca-
tion (Huang et al., 1979). In PET-only, attenuation and scatter correction
(AC, SC) are performed by using measured attenuation coefﬁcients of
511 keVphotons derived from images acquiredwith integrated standard
transmission sources (Watson, 1997). In PET/CT, the X-ray transmission
source (up to 140 kVp) is used to generate CT images that can be used to
calculatemaps of attenuation coefﬁcients at 511 keV (Burger et al., 2002;
Carney et al., 2006; Kinahan et al., 1998). Attenuation correction based on
transmission source imaging is not an option in PET/MR imaging given
the lack of rotating transmission sources in the combined system. Instead
various approaches have beenpresented (Bezrukov et al., 2013) to derive
subject-speciﬁc attenuation information either from an atlas (Hofmann
et al., 2009) or from post-acquisition MR image processing (Keereman
et al., 2013; Wagenknecht et al., 2013). Commercial PET/MR systems
today have a segmentation routine implemented that separates MR im-
ages acquired with dedicated sequences either into three tissue classes
(air, lung and soft tissue) (Schulz et al., 2011) or four tissue classes (air,
lung, fat and soft tissue) (Martinez-Möller et al., 2009). Neither segmen-
tationmethoddoes account for bone tissue attenuation,with attenuation
values that are higher than those air, lung, fat and water. Ignoring bone
during PET attenuation correction is known to cause a distorted and bi-
ased distribution of the reconstructed PET activity concentration (Kellerx x
y
CT DWFS
Simulated
Plaster 
µ=0.14 cm-1
Soft tissue 
µ=0.10 cm-1
B
y
patient and (B) cylinder phantom followingMR-based attenuation correction that ignores
map from standardMR-AC (acquired in A, simulated in B). The DWFS underestimates the
response (LOR) depends on the product of the bias of the attenuation coefﬁcient and the
for LORs through the center (y N x), a bias is introduced in the projections that propagate
208 F.L. Andersen et al. / NeuroImage 84 (2014) 206–216et al., 2013). This may have particular implications for brain imaging as
discussed by Catana et al. (2010).
Fig. 1 illustrates the bias originating from ignoring bone in PET/MR
imaging of the brain. The reconstructed voxel value in any point of a
PET image is affected by the measured intensity along lines-of-response
(LORs) that traverse that voxel. The intensitymust be corrected for atten-
uation prior to reconstructing the emission image. The attenuation cor-
rection factor along a given LOR is calculated based on the integral of
the tissue attenuation values along that LOR. Fig. 1 shows a cross section
of a human head and a cylindrical “skull” phantom. LORs near the edge,
traversing the skull at an oblique angle have a longer path through skull
bone than central LORs. Therefore, total attenuation along these LORs is
affected more by the higher bone attenuation than that of central LORs.
Consequently, the overall effect of neglecting bone attenuation is likely
to be larger at the edge than at the center, thus, leading to a regionally
variable bias.
The purpose of our studywas to assess the regional and absolute bias
introduced from neglecting bone during MR-AC of combined PET/MR
images of the brain. We employ phantom and clinical data from an on-
going commissioning of a fully-integrated,whole-body PET/MRI system.
Materials and methods
Patient studies were performed using a fully-integrated PET/MR sys-
tem (Biograph mMR, Siemens Healthcare) (Delso et al., 2011) and, for
the purpose of reference imaging, on a whole-body PET/CT system
(Biograph TruePoint64 or Biograph mCT64, Siemens Healthcare)
(Jakoby et al., 2011). All PET systems were normalized using [68Ge]-
cylinder phantoms and cross calibrated using a common [18F]-ﬁlledA
Fig. 2. Skull-like phantom with uniform [18F]FDG activity distribution (25 kBq/mL) inside the m
covers 10 cm axially (A); the width of the skull is about 12 mm as seen on the transaxial CT im
tivity concentration from simulated MR-AC.phantom. Decay-correction of the PET data from either the PET/CT or
the PET/MR examination was always performed to the start time of the
ﬁrst of the two PET examinations.
Based on Fig. 1A a skull-like phantom was prepared (Fig. 1B) to
assess the effect of bone in MR-AC. Subsequent ﬁndings were tested in
patients who were recruited from an ongoing study on the clinical
value of PET/MR imaging in dementia.
Phantom study
A 2 L plastic bottle was ﬁtted with a layer of approximately 12 mm
non-synthetic plaster (Gypsona, BSN Medical, Hannover, Germany).
The plaster ring extended over 10 cm axially in the center of the phan-
tom (Fig. 2A). A total of 50 MBq of [18F]FDGwas injected into the phan-
tom and distributed uniformly. The phantom was placed on the bed
parallel to the main axis of the PET/CT, and subsequent CT (120 kVp,
380 mAs, 3 mm slices) and emission scanning were performed over
the central phantom (1-bed) layered with the plaster. CT images of the
phantom (Fig. 2B) demonstrated a mean CT-density of the plaster of
(814 ± 65) HU, corresponding to bone attenuation at 511 keV (linear
attenuation coefﬁcient: 0.140 cm−1, (Carney et al., 2006)).
PET images of the phantom were reconstructed following CT-based
attenuation correction using the original CT images (PETCT), and the CT
images with the image values representing plaster above 50 HU being
replaced by the attenuation values of brain tissue of 36 HU (PETSOFT).
Here the attenuationmap resembles that of a standardMR-based atten-
uation map following the Dixon-Water–Fat-segmentation (DWFS)
(Martinez-Möller et al., 2009), that is the standard method in the
fully-integrated PET/MR (Delso et al., 2011). PET image reconstructionB
C
imicked “brain”. The “skull”was simulated by a layer of plaster. The high-density “skull”
age (B). Concentric annuli of 5 mmwidth are used to quantify regional changes in the ac-
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tationmaximization (AW-OSEM) (4 iterations 21 subsets, 4 mmGauss-
ian postﬁlter) algorithmwithout resolutionmodeling andwithout using
time-of-ﬂight (TOF) in order to closely resemble the PET/MR image
reconstruction. PET image matrix size was 336 × 336 voxels, with
(0.8 × 0.8 × 3) mm voxel size. A 4 mm Gaussian post-reconstruction
ﬁlter was applied.
The PET images were analyzed using 10 concentric annulus regions
of 5 mmwidth (Fig. 2C) and themean activity concentrations (kBq/mL)
were calculated for all annuli placed over a central transaxial image
plane traversing PETCT and PETSOFT. For each annulus, we report the %-
differences (Δ%) i.e., (PETSOFT−PETCT) / PETCT.Patient characteristics
19 patients (9 male, 10 female, mean age (68 ± 9) y, range: 43 y–
85 y) under evaluation for suspected dementia were referred for an
[18F]FDG-PET/CT study and included in this study. Prior approval was
obtained from the local Ethics Committee and all patients were able to
give informed consent. Patients were injected with 200 MBq of [18F]
FDG. Ten patients were imaged on PET/MR ﬁrst and then on PET/CT
while 9 patients were imaged in the reverse order of examinations
(Table 1), in an attempt to limit the effects from changes in the tracer
uptake and distribution as a function of the post-injection time of the
tracer (Krak et al., 2003).PET/CT acquisition
Patients were positioned head-ﬁrst supine on the PET/CT with the
arms down and the head positioned in the standard head holder at-
tached to the bed. PET/CT imaging was performed at a single PET bed
position; with the protocol including a topogram scan, a spiral CT
(120 kVp, 36 mAs, 5 mm slice width) and a 10 min 3D-emission scan.Table 1
Summary of 19 patients referred for an [18F]FDG PET/CT for suspected dementia diagnosis
and imaged with PET/CT and PET/MR for a single injection of activity. Patients 1–10
underwent PET/MR imaging ﬁrst, followed by PET/CT imaging (delay: (66 ± 9) min);
patients 11–19 were scanned in reverse order of examinations (intra-scan delay: (46 ±
7) min). M = Male, F = Female.
Subject Sex Age (y) Inj. dose
(MBq)
Pi time (min)
PET/MR
Pi time (min)
PET/CT
Time difference
(min)
PET/MR ﬁrst, followed by PET/CT
1 M 70 202 35 59 −24
2 F 66 200 41 60 −19
3a M 71 201 41 87 −46
4 F 65 199 32 67 −35
5 M 76 204 43 63 −20
6 M 71 199 43 63 −20
7 F 65 200 38 68 −30
8a M 81 198 46 61 −15
9 F 68 200 45 73 −28
10 F 85 200 40 57 −17
PET/CT ﬁrst, followed by PET/MR
11 F 43 205 81 41 40
12a F 70 201 74 45 29
13 M 62 203 97 62 35
14 F 77 201 91 50 41
15 F 71 199 90 45 45
16 M 69 201 83 40 43
17a M 61 196 82 48 34
18 M 54 202 75 46 29
19 F 72 196 69 39 30
a Indicates patient with severe artifacts in the MR attenuation map due to dental
implants.PET/CT image reconstruction
PET images from the PET/CT were reconstructed following CT-AC
employing the standard bi-linear scaling approach (Carney et al.,
2006). PET images were reconstructed using AW-OSEMwithout resolu-
tion modeling and without using TOF, as these options were not avail-
able on our PET/MR system at the time of this study. Reconstructed
PET images were 336 × 336 matrix size, 4 iterations, 21 subsets and
400 × 400matrix size, 4 iterations, 24 subsets on the Biograph TruePoint
PET/CT and the BiographmCT, respectively. In all cases a 4 mmGaussian
post-reconstruction ﬁlter was applied, and the reconstructed PET voxel
size was 0.8 × 0.8 × 3 mm.PET/MR acquisition
Patients were positioned in the PET/MR in supine position with the
arms down. The head was positioned in the head–neck coil. In case
the patients were examined on PET/MR ﬁrst (Table 1, patients 1–10),
simultaneous 3D PET/MR imaging of a single PET-bed position was
followed by a single-bed PET/CT scan at a mean time interval of
(24 ± 9) min. In cases of the PET/MR imaging being performed after
the PET/CT examination (Table 1, patients 11–19), themean time inter-
val between scans was (36 ± 6) min. In each case emission acquisition
time was 10 min.
MR imaging included an in-/opposed-phase sequence for Dixon-
Water–Fat segmentation (DWFS) (Martinez-Möller et al., 2009) as
well as T1w- and T2w-imaging. In- and opposed phase imaging was
based on a 3D VIBE-Dixon sequence with a repetition time (TR) of
3.6 ms, echo times (TE's) of 1.23/2.45 ms, a ﬂip angle of 10°, voxel size
4.1 × 2.6 × 3.1 mm3 and an acquisition time of 19 s. Additional ana-
tomical imaging using T1 was performed as follows: 3D MPRAGE se-
quence, TR 1900 ms, TE 2.44 ms, ﬂip angle 9°, voxel size 1.0 × 1.0 ×
1.0 mm3 and acquisition time 5 min. Anatomical imaging using T2
was performed as follows: Turbo spin echo (TSE) sequence, TR
6000 ms, TE 96 ms, ﬂip angle 150°, voxel size 0.7 × 0.7 mm2, slice
thickness 4 mm and an acquisition time of 1.25 min. All MR sequences
used a parallel imaging factor of 2.Bone tissue extraction and PET/MR image reconstruction
For each subject, CT imageswere co-registered to the PET/MR images
using a rigid alignment procedure (minctracc, McConell Imaging Center,
Montreal). First, the patient bed and head-holder were extracted manu-
ally from the CT images using an oval ROI (OsiriX software) applied to
each transverse CT image. Subsequently, a CT-based bone representation
was deﬁned by masking all CT voxels from the co-registered CT images
within the oval ROI with a CT attenuation value of 100 HU, and above.
The bone attenuation values were then converted from HU to linear at-
tenuation coefﬁcients at 511 keV by using the standard bi-linear scaling
approach (Carney et al., 2006) as implemented in our PET/CT systems.
Three attenuation maps were created. First, the standard MR-based
attenuation following DWFS was used, thus, accounting for air, lungs,
fat and soft tissue, but not bone (MR_DWFS). Second, the co-registered
bone attenuation map was superimposed on the DWFS-map, thus, re-
placing existing DWFS-based attenuation values with those of bone
(MR_Bone). The MR-based attenuation map then accounted for air,
lungs, fat, soft tissue and bone. For the third reconstruction, the co-
registered standard CT attenuation map replaced the DWFS attenuation
map in the volume covered by the CT (MR_FullCT). The three attenua-
tionmapswere used for PET/MR reconstruction, resulting in PETMR_DWFS,
PETMR_Bone and PETMR_FullCT.
The same PET reconstruction parameters were used for the PET/MR
data as for the PET/CT data,with the only change being thematrix size of
344 × 344 and a reconstructed PET voxel size of 0.8 × 0.8 × 2 mm.
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Visual and quantitative analysis was performed of the reconstructed
PET images from the PET/CT and the PET/MR examinations using the
three approaches to MR-AC. Similar to the phantom study (Fig. 2) we
used 10 regions-of-interest (ROI) represented by successive 5 mm de-
formed annuli that followed the exterior cortical layer and extending
from the cortex inwards to the center of the transaxial image plane
(Fig. 3). These ROIs were delineated manually on a transaxial T2w-MR
image traversing the central basal ganglia. For each patient and image
reconstruction the mean FDG activity concentration was calculated for
each of the 10 homeomorphic annuli: PETCT, PETMR_DWFS, PETMR_Bone,
and PETMR_FullCT.
We report %-differences (Δ%) per annulus and patient for PETMR_DWFS
relative to PETCT. We also report Δ% averaged across two groups
depending on the scan order of PET/MR and PET/CT for PETMR_DWFS,
PETMR_Bone and PETMR_FullCT relative to PETCT. Finally we report %-differ-
ences (and standard deviation) for PETMR_DWFS relative to PETMR_Bone
and PETMR_DWFS relative to PETMR_FullCT again averaged across all pa-
tients. For this analysis, four of the 19 patients had to be excluded since
the PET images from the PET/MR were distorted by signal voids arising
from susceptibility artifacts caused by dental ﬁllings (Keller et al., 2013).Results
Phantom study
A signiﬁcant bias of the reconstructed and attenuation-corrected PET
images is found in case bone (plaster) is not accounted for duringAC. This
is illustrated in Fig. 4 that shows central transaxial image planes through
the original andmodiﬁed CT and PET images using the corresponding at-
tenuationmaps. An overall absolute reduction in reconstructed PET activ-
ity in case bone is ignored during AC is seen. This is demonstrated when
comparing Fig. 4C (PETCT) and Fig. 4D (PETSOFT). The calculatedΔ% shows
a radial bias that was largest (up to 14%) in the most exterior region
representing the cortex and lowest (7%) in the central region of the phan-
tom (Figs. 4E and F).Fig. 3. (A) Transaxial T2w MR image traversing the central basal ganglia and (B) representatioClinical PET/MR study
The reconstructed tracer distribution of the phantom study above
was replicated in our patient studies. Fig. 5 exempliﬁes the relative dif-
ference of the reconstructed PET activity distribution in patients follow-
ing standard DWFS MR-AC (PETMR_DWFS) in comparison to PET images
following CT-AC (PETCT). The regional variation of the AC-PET distribu-
tion in PETMR_DWFS is clearly seen as a volumetric effect with the highest
relative difference in the cortical region. In addition, the effect is equally
visible on the coronal and sagittal slices, thereby reﬂecting the “spheri-
cal” nature of the skull.
The reconstructed PET activity concentrations in PET/MR images fol-
lowing MR-AC in reference to PETCT for all 19 patients are illustrated in
Fig. 6 as the relative differenceΔ%(PETMR_DWFS, PETCT). Two distinct ob-
servations can bemade in this ﬁgure. First, an overall sign-inversion, de-
pendent on the scan order due to changes in the physiological tracer
uptake between the two scans. Second, a common, gradual decrease
of Δ%(PETMR_DWFS, PETCT) is observed from the center to the cortex
across all patients, independent of the scan order.
Fig. 7 further exempliﬁes the visual and quantitative results. For bet-
ter visual comparison, the PETCT scale is adjusted to that of the PET/MR
images to account for the increased physiological uptake of FDG during
the intra-scan delay of 17 min. Note, the substantial decrease of
reconstructed tracer activity in regions of PETMR_DWFS close to the
skull relative to the center (panel I). This effect is largely removed in
PETMR_Bone (J) and even further in PETMR_FullCT (K),while residual differ-
ences can be attributed to changes of the tracer uptake and distribution
during the PET/CT and PET/MR scans. Finally, (L) and (M) show the rel-
ative difference of (F, G) in reference to (E), i.e. involving only PET data
acquired at one time point on PET/MR.
The visual and quantitative bias as exempliﬁed in the case study in
Figs. 5 and 7 is replicated across all subjects (Figs. 8A–C). Note, four of
the 19 patients had to be excluded from detailed analysis (Table 1, de-
noted by “*”) due to dental work causing severe MR image artifacts
that caused a biased MR-based attenuation map and subsequent arti-
facts in the reconstructed PET images (Keller et al., 2013).
The gradual radial change of Δ% following MR_DWFS is nicely illus-
trated in Fig. 8A by averaging over all patients (from Fig. 6). This bias isn of the homeomorphic ROI's extending from the cortex to the center of the image plane.
Fig. 4. Skull-type phantom: (A) transaxial image planes through the original CT, (B) segmented CT with plaster (“bone”) values set to brain tissue, simulating DWFS MR-AC, (C, D) corre-
sponding PET images after CT-AC using the image information in (A) and (B), (E) difference (Δ%) of the PET image values in (D) relative to (C), and (F) relative difference (Δ%) in the
annulus ROI from Fig. 2C averaged across transverse image planes using the color coding from Fig. 2C.
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(MR_Bone, Fig. 8B) or when using the full CT for AC (MR_FullCT,
Fig. 8C). The improvements from doing PETMR_Bone or PETMR_FullCT over
PETMR_DWFS are illustrated in Figs. 8D and E, respectively, involving
only PET-data from PET/MR without being affected by physiological
changes. In both cases there are improvements in all ROIs. The improve-
ment increases monotonically towards the skull, from ~4% (center) to
~17% (cortex) for MR_Bone and from ~6% (center) to ~27% (cortex)
for MR_FullCT.
Discussion
This studywasmotivated by observations of differences in the cortical
activity distribution post [18F]FDG injection of patients with suspected
dementia undergoing combined PET/MR imaging at our institution.
FDG-PET images of the brain from combined PET/MR showed a markeddifference in the decay-corrected tracer activity distribution when
compared to corresponding PET images from the single-injection
FDG-PET/CT following standard CT-AC (Andersen et al., 2012).
This is exempliﬁed in Fig. 5. Therefore,wehypothesized that not account-
ing for bone tissue during standard MR-AC causes the reconstructed PET
activity distribution in PET/MR to be biased (Fig. 1).
Our study is based on the acquisition of phantom and patient data
using a fully-integrated PET/MR system with an implemented 4-tissue
class DWFS MR-AC (Martinez-Möller et al., 2009).
Our simpliﬁed “skull” phantomwasﬁlledwith a uniform activity con-
centration in water, and wrapped with layers of plaster, thus, mimicking
a simpliﬁed 2D-brain phantom including the skull (Fig. 2).We observed a
reduction of the mean activity values in the radial direction towards the
skull in the transaxial PET/CT images following simulatedMR-ACwithout
considering bone attenuation values. The 7% difference in the central an-
nulus region is also visually noticeable (Figs. 4C and D). The measured
cm-1
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0
0
-40
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1000
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%
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Fig. 5. Example PET/MR study of patient 10 (Table 1) following DWFS MR-AC: (A) T1w MR, (B) relative %-difference Δ%(PETMR_DWFS, PETCT) and (C) PETMR_DWFS/MR fusion overlay.
Fig. 6. Plots of subject-speciﬁc relative %-differences, Δ%(PETMR_DWFS, PETCT) of reconstructed mean PET activity concentrations in the homeomorphic regions (Fig. 3). Separation is pro-
vided for subjects undergoing PET/MR prior to PET/CT (left panel) and those undergoing scans in reverse order (right panel). Note, differences are plotted on the same absolute scale (max.
40%) except that the zero-crossingwas shifted for visibility in the right panel. Patient 3, 8, 12 and 17 had severe artifact in theDWFS attenuationmapdue to the presence of dental implants
(Table 1).
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Fig. 7. Case study (patient 10, Table 1) with set of transaxial image planes: (A) original MR attenuation map (MR_DWFS), (B) MR attenuation map with superimposed bone attenuation
values (MR_Bone), (C)MR replacedwith co-registered full CT (MR_FullCT) and (D) original CT (CT). Image planes (E–H) represent the corresponding PET images reconstructed following
AC using the attenuation information in (A–D). The scale in (H) was adapted to account for the change in tracer distribution from the elapsed time between the scans. Δ%-images with
respect to PETCT are shown for PETMR_DWFS (I), PETMR_Bone (J) and PETMR_FullCT (K) demonstrating a markedly reduced gradient effect in (J) and (K). Panels (L) and (M), respectively,
show the relative %-difference image of (F) and (G) with respect to PETMR_DWFS (E).
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lem is caused by the differential average path length through bone struc-
tures for photons originating at the center and at the edge. The argument
can easily be transferred from the 2D cylinder to a 3D sphere, and to the
brain. Both, the visual and quantitative observations from the phantom
study are replicated in our clinical patient population that included 19
patients with dementia. PET/MR images following DWFS MR-AC
(PETMR_DWFS) showed lower PET signal in cranio-lateral cortical regions
of the brain relative to the central regions when compared to PETCT.
This is consistent for all 19 patients (Fig. 6). The observed shift (30%) of
the relative difference of PET/MR and PET/CT images is attributed to the
reverse scan order in the twopatient groups (Table 1) and the continuous
uptake of [18F]FDG during the intermittent time between scans. The FDG
uptake in brain tissue iswell described fromdynamic studies. It continues
to increase for about 2 h, but with steadily decreasing slope as the maxi-
mum is approached (Hasselbalch et al., 1999; Spence et al., 2004). There-
fore, the difference of FDG uptake between two time points does not only
depend on the time difference, but also on the absolute time after injec-
tion. In our study, the two differences presumably are of about the
samemagnitude, since for the groupwith the longer of the two intervals,
the ﬁrst scan is also started later.Fig. 8 summarizes the mean differences in AC-PET following stan-
dard and modiﬁed AC across subjects without dental artifacts. Using
state-of-the-art PET/MR imaging and implementations of MR-AC we
found an average bias of 10–15 percentage points between center and
cortex (Fig. 8A) of the PET activity concentration relative to PET/CT in
a sample axial slice through the basal ganglia. This bias may vary with
the density, thickness and curvature of the cortical bone structures
(Catana et al., 2012).
When bone attenuation was accounted for (MR_Bone and
MR_FullCT) the gradient effect of the reconstructed PET activity distri-
bution was removed with the mean relative %-differences being the
same across all ROIs (Figs. 8B and C). ForMR_Bone AC the relative %-dif-
ference is around−15% or+15% for all homeomorphic ROIs depending
on the scan order of PET/MR and PET/CT (Fig. 8B). The difference be-
tween the PET images following standard and MR_Bone attenuation
correction (PETMR_DWFS and PETMR_Bone) represents a smooth function
of the distance from the skull with amaximum difference in the cortical
region of −17% (Fig. 8D). When replacing the MR-based attenuation
map with the co-registered CT-based attenuation map including bone,
soft tissue and intermediate values, as calculated from standard CT-AC
(Carney et al., 2006), the relative %-difference between the PET/MR
AB
C
D
E
Fig. 8. Relative %-difference values for each of the homeomorphic ROI's averaged across all included patients. Difference values are shown relative to PET/CT for: (A) standard PET/MR—
(PETMR_DWFS), (B) PET/MR with superimposed bone attenuation map— (PETMR_Bone) and (C) PET/MR with full CT-based attenuation map— PETMR_FullCT. The difference values in panels
(D) and (E) showdirectly the effect of applyingMR_Bone andMR_FullCT compared toMR_DWFS. The values in (D) and (E) correspondwell to the differences in (A–B and A–C). Note, the
observed absolute difference between two groups is the result of both the physiological uptake (sign reversed with scan order) and a bias (not reversed) from the different corrections
performed. Patient 1 (Table 1) was excluded from inclusion in C and E due to loss of data for PET reconstruction.
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ROIs (Fig. 8C).
Although adding bone to the DWFS attenuation map removes the
observed radial differences in the PET/MR images, we observed a resid-
ual difference of AC-PET values of 10%, or less between PETMR_Bone and
PETMR_FullCT (Figs. 8B, C). This difference may be caused by two effects.
Firstly, the implementation of the DWFS attributes a constant value of
0.100 cm−1 to soft tissue, while the CT-based attenuation values inside
the skull are slightly lower (0.0974 cm−1) and regionally variable.
Secondly, the full_CT attenuation map is slightly larger than the
DWFS-map, adding a few mm of soft tissue around the skull which
more than compensates the lower values inside. The overall result is a
larger attenuation correction, weighted towards the edge, cf. Fig. 8D
versus Fig. 8E.
This study demonstrates the signiﬁcance of the resulting underesti-
mation of attenuation in PET/MR imaging of the brain using a standard
4-class segmentation method (Martinez-Möller et al., 2009). Both,phantom and clinical data illustrate a bias of attenuation-corrected
and reconstructed PET activity concentrations. More importantly, this
bias is spatially variable with a gradient pointing from the skull towards
the center of the brain,most prominently seen on transaxial PET images
traversing the central brain, but equally important in coronal and sagit-
tal views (Fig. 5).
These ﬁndings are also conﬁrmed by Hitz et al (Hitz et al., 2012) in a
study of 32 patientswith suspected dementia undergoing head-to-head
comparisons of single-injection [18F]FDG-PET/CT and -PET/MRI (Hitz
et al., in review). Speciﬁcally, a voxel-based analysis revealed consis-
tently lower tracer signal in PET/MR images following DWFS MR-AC in
the cranio-lateral neocortex relative to the center, a ﬁnding that is in
agreement with our results (Figs. 6 and 8). Hitz and co-workers further
demonstrated a subsequent difference in observer-based rating of the
PET/CT and PET/MR data in 20% of their patients. This illustrates a clin-
ical signiﬁcance of the spatially variable bias of attenuation corrected
PET activity in standard PET/MR.
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served (see Fig. 5), but here the shape of the bone is more irregular, and
the bone layer is often quite thin. Therefore, we do not see the same
general radial decrease of reconstructed activity near the base of the
brain, as we do close to the skull in the transaxial planes. Furthermore,
MR susceptibility artifacts add another level of complexity to MR-
based attenuation correction at the skull base. Addressing this issue
falls outside the scope of this paper.
It is important to acknowledge that accurate quantiﬁcation is essen-
tial to the clinical application of PET in the brain. Over the past decades a
concerted effort has collected data of the clinical impact of PET brain im-
aging of a high quality enough to obtain FDA approval. This includes
FDG (Silverman, 2004) and [18F]Florbetapir (Clark et al., 2012) for the
use in dementia correlated with autopsy data. There are several other
[18F]-labeled tracers targeting amyloid in the brain, that are in the
process of being approved. Further, a large multicenter study, the
Alzheimer's Disease Neuroimaging Initiative (ADNI), has been funded
to deﬁne the progression of Alzheimer's disease though biomarkers
for the purpose of scientiﬁc investigation, teaching or planning clinical
research studies. For primary brain tumors threshold values have been
meticulously established through multiple biopsies to best identify
and deﬁne boundaries of primary brain tumors using e.g. [18F]Fluoro-
Ethyl-Tyrosin (FET) (Pauleit et al., 2005) for planning preoperatively
or for radiation therapy. All of the above applications are dependent
on the ability to accurately quantify the tracer concentration in tissue.
The brain imaging data acquired with the present state of combined
PET/MR technology is likely to fail the site qualiﬁcation necessary to be
accepted in multicenter studies such as ADNI and for the clinical trials
running using brain amyloid modifying agents (Ostrowitzki et al.,
2011). Furthermore, accurate neuroreceptor quantiﬁcation will not be
possible, whether it is based on absolute measurement or applies a ref-
erence tissue model, typically with cerebellum as the reference.
In order to address the needs for absolute quantiﬁcation laid out
above, alternative strategies towards AC for brain studies are required.
A number of approaches have been proposed that include machine
learning algorithms in combination with an atlas database, bone seg-
mentation based on ultra-short echo time (UTE) MR imaging as well
as special image reconstruction algorithms that estimate, both, the
emission activity and the attenuation from the PET emission data
(Bezrukov et al., 2013).
Limitations
Our study has several limitations. Firstly, we simulated bone tissue
by plaster, which has a slightly lower density than cortical bone. There-
fore, the numerical results from the phantom and the patient study can-
not be compared directly. Secondly, a similar intra-scan delay in the two
patient groups was challenged by logistics issues during routine clinical
operation of PET/CT and PET/MR in our department. Thirdly, our original
subject population was reduced by drop-outs caused by severe dental
artifacts in PET/MR, which could not be corrected for in view of a lack
of retrospective correction algorithms for dental work. Fourthly, our
data analysis approach is best suited for quantiﬁcation of the global ra-
dial gradients manifest with DWFS MR-AC. In attenuation correction
strategies using UTE where regional aberrations may predominate a
data driven approach may be more appropriate (Catana et al., 2010).
Conclusion
Accurate attenuation correction is needed to achieve quantitative
PET images. Failure to account for bone attenuation during standard
MR-based attenuation correction of PET/MR data introduces a signiﬁ-
cant bias in the area of the cortex as compared to PET/CT following stan-
dard CT-AC. Of note, this bias is spatially variable being highest in the
outer cortical structures and lower in the central brain. The effect can
be understood from simple ﬁrst principles of PET imaging andcorrection. Both absolute differences and regional variations can be
markedly reduced when accounting for bone attenuation as part of
theMR-AC. Therefore, reﬁnements to existingMR-ACmethods, or alter-
native strategies need to be found prior to adopting PET/MR imaging of
the brain in clinical routine and research.
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